Cabaletta Bio
Clinical trials sponsored by Cabaletta Bio, explained in plain language.
-
MS trial withdrawn before it began: CAR T-Cell hope on hold
Disease control TerminatedThis study aimed to test a new treatment called CABA-201, a CAR T-cell therapy made from a patient's own immune cells, for people with multiple sclerosis (MS). The goal was to see if it was safe and could control the disease by targeting and resetting the immune system. However, …
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take on rare Muscle-Weakening disease
Disease control OngoingThis early-stage study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes severe muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The …
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC